Related Experiment Video
Updated: Jun 22, 2025
Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems
Published on: August 23, 2019
Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome
Sylvia Cruchet Muñoz1, Sandra Verbeke Palma2, Lydia Lera Marqués3
1Instituto de Nutrición y Tecnología de los Alimentos "Dr. Fernando Monckeberg", Área Nutrición Humana, Universidad de Chile, El Líbano 5524, Macul, Santiago 7830490, Chile.
Insights
This study found that Bifidobacterium longum 35624 significantly improved irritable bowel syndrome (IBS) symptoms in children and adolescents. These benefits were observed even in participants with vitamin D deficiency, suggesting a potential therapeutic role.
Area of Science:
- Gastroenterology
- Microbiology
- Pediatrics
Background:
- Irritable bowel syndrome (IBS) and vitamin D deficiency are prevalent in Latin American children.
- Bifidobacterium longum 35624 has demonstrated efficacy in improving IBS symptoms in adults.
Purpose of the Study:
- To investigate the effects of Bifidobacterium longum 35624 on gastrointestinal symptoms in children and adolescents with IBS.
- To explore the relationship between probiotic intervention and baseline vitamin D status.
Main Methods:
- A 12-week, open-label study in 64 children and adolescents (8-18 years) using Bifidobacterium longum 35624 (1 × 10^9 CFU).
- Gastrointestinal symptoms were assessed using the adapted IBS Severity Scoring System (IBS-SSS) and Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS).
- Serum vitamin D levels were measured at baseline.
Main Results:
- Significant improvements in IBS-SSS domains and composite scores were observed at weeks 6 and 12 (p < 0.0007).
- 96.6% of participants showed clinically meaningful improvement, with a shift from moderate/severe to mild/remission IBS categories (p < 0.0001).
- QPGS scores significantly decreased, while improvements were not sustained during the washout period. Low vitamin D did not correlate with IBS severity or probiotic response.
Conclusions:
- Bifidobacterium longum 35624 may effectively improve IBS symptoms in pediatric populations, irrespective of vitamin D status.
- Further randomized controlled trials are warranted to confirm these findings and explore the interplay with vitamin D.
Abstract:
Irritable bowel syndrome (IBS) and vitamin D deficiency are common among children in Latin America. Previous studies show that Bifidobacterium longum35624TM improves IBS symptoms in adults. This real-world, single-arm, open-label study conducted in Chile investigated the effects of B. longum 35624 (1 × 109 colony-forming units, 12 weeks) on gastrointestinal symptoms (adapted IBS severity scoring system [IBS-SSS]; adapted Questionnaire on Pediatric Gastrointestinal Symptoms [QPGS], and Bristol Stool Form Scale) in 64 children and adolescents (8-18 years) and explored the relationship with baseline vitamin D status. Improvements in all IBS-SSS domains and composite score were observed at week 6 and 12 (p < 0.0007 versus baseline), with 98.3% of participants experiencing numerical improvements in ≥3 domains. Clinically meaningful improvement was seen in 96.6% of participants. The distribution of IBS-SSS severity categories shifted from moderate/severe at baseline to mild/remission (p < 0.0001). Improvements were not maintained during the two-week washout. Low baseline serum vitamin D levels did not correlate to IBS severity or probiotic response. QPGS significantly decreased from baseline to week 6 (p = 0.0005) and 12 (p = 0.02). B. longum 35624 may improve IBS symptoms in children and adolescents, even those with vitamin D deficiency. A confirmatory randomized controlled trial and further exploration of probiotic response and vitamin D status are needed.
More Related Videos
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management